Ask AI

Sequencing CAR T-Cell, Bispecific Antibody, and ADC-Based Therapies in Relapsed/Refractory Multiple Myeloma

Clinical Thought
Clinical Thought Start Activity
This activity is available for 0.25 CME/CE credit(s).

Released: October 20, 2026

Expiration: April 19, 2027

See Activity Collection

In relapsed/refractory multiple myeloma, prior therapy can affect subsequent treatment efficacy, highlighting the importance of thoughtful sequencing and consideration of alternative targets. In this commentary, expert faculty discuss sequencing of antibody–drug conjugates, bispecific antibodies, CAR T-cell therapy, and other novel treatment modalities for patients with relapsed/refractory multiple myeloma.

Sequencing Therapies in RRMM

Pre Assessment

Assess your current knowledge and clinical approach before beginning your ClinicalThought.
1.

How many people with multiple myeloma do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

You are planning therapy sequencing for a patient with MM experiencing disease relapse. In considering use of BCMA-targeted therapies, which of the following BCMA-directed treatment modalities is suggested to be associated with an increased risk of BCMA binding-site mutations and BCMA loss when patients relapse during treatment?

4.

Based on current evidence in R/R MM, which novel therapeutic approach is supported by data demonstrating improved outcomes?